BLCO vs. RXST, STAA, EYE, COO, HALO, OGN, LNTH, OPCH, BBIO, and APLS
Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include RxSight (RXST), STAAR Surgical (STAA), National Vision (EYE), Cooper Companies (COO), Halozyme Therapeutics (HALO), Organon & Co. (OGN), Lantheus (LNTH), Option Care Health (OPCH), BridgeBio Pharma (BBIO), and Apellis Pharmaceuticals (APLS). These companies are all part of the "medical" sector.
Bausch + Lomb (NYSE:BLCO) and RxSight (NASDAQ:RXST) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Bausch + Lomb has a net margin of -7.81% compared to RxSight's net margin of -54.57%. Bausch + Lomb's return on equity of 3.60% beat RxSight's return on equity.
RxSight received 12 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 66.67% of users gave RxSight an outperform vote while only 38.71% of users gave Bausch + Lomb an outperform vote.
RxSight has lower revenue, but higher earnings than Bausch + Lomb. RxSight is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.
In the previous week, RxSight had 17 more articles in the media than Bausch + Lomb. MarketBeat recorded 39 mentions for RxSight and 22 mentions for Bausch + Lomb. RxSight's average media sentiment score of 0.47 beat Bausch + Lomb's score of 0.40 indicating that RxSight is being referred to more favorably in the news media.
Bausch + Lomb has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.
Bausch + Lomb currently has a consensus price target of $19.45, suggesting a potential upside of 27.32%. RxSight has a consensus price target of $60.63, suggesting a potential downside of 1.29%. Given Bausch + Lomb's higher possible upside, research analysts plainly believe Bausch + Lomb is more favorable than RxSight.
11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 21.1% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
RxSight beats Bausch + Lomb on 11 of the 18 factors compared between the two stocks.
Get Bausch + Lomb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch + Lomb Competitors List
Related Companies and Tools
